Research Chemical Designation & Liability
Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.
Semax
Cognitive & Nootropic
Molecular Dossier
- Rank Index: 17
- Status: Pending Reclassification
- What does this mean?
- Molecular Structure: Heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro)
About Semax
Synthetic ACTH(4–7) analog studied for cognitive enhancement, neuroprotection, and BDNF upregulation. Selectively active at melanocortin receptors. As of the FDA's February 2026 regulatory shift announced by HHS Secretary RFK Jr., Semax is among the ~14 peptides expected to move from Category 2 (restricted) back to Category 1 compounding status. The formal ruling is pending the July 23–24, 2026 PCAC committee meeting. Until then, Semax remains Research Use Only (RUO) for laboratory investigation.
Clinical Focus
Cognitive Enhancement
Archival Aliases
Brain Booster, Russian Focus
Frequently Asked Questions
What are the strict legal and safety limitations for research-grade peptides?
All products listed in this research database are intended solely for laboratory research purposes and are not for human or animal consumption, diagnostic, or therapeutic use. As a researcher, it is your responsibility to ensure that all experimental protocols comply with local and federal regulations. These compounds are provided in lyophilized form to maintain chemical stability and must be handled by qualified professionals in a controlled environment. Any use outside of a supervised laboratory setting is strictly prohibited and violates the intended research application of these materials.
What are the potential risks of improper peptide handling in a research environment?
Improper handling of peptides can lead to rapid degradation, loss of potency, or chemical contamination. Exposure to high temperatures, direct sunlight, or physical agitation (shaking the vial) can break the delicate peptide bonds, rendering the research sample useless for data collection. Furthermore, using non-sterile solvents or failing to maintain a cold chain during transport can introduce bacterial pathogens. Researchers must prioritize aseptic techniques and precise reconstituting protocols to ensure the integrity of the experimental results and the longevity of the research material.
How does Semax affect BDNF expression?
Semax has been shown to rapidly increase the levels of Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF) in the hippocampus and frontal cortex. This neurotrophic support underlies its ability to improve memory consolidation and protect neurons from oxidative stress and ischemic damage.
What is semax and where was it developed?
Semax is a synthetic heptapeptide derived from the ACTH(4-10) sequence (Met-Glu-His-Phe-Pro-Gly-Pro). It was developed in the 1980s by the Institute of Molecular Genetics, Russian Academy of Sciences, and has been used clinically in Russia and Eastern Europe as an approved drug for stroke recovery, cognitive decline, and optic nerve diseases. It is not FDA-approved and is classified as Research Only in the U.S.
How does semax enhance cognitive function?
Semax's nootropic effects operate through several pathways: (1) it upregulates BDNF (Brain-Derived Neurotrophic Factor) and its receptor TrkB, directly promoting neuronal growth and synaptic plasticity; (2) it stimulates the ACTH/melanocortin receptor system, enhancing attention and working memory; (3) it modulates dopaminergic and serotonergic systems, improving mood and motivation; and (4) it has anti-inflammatory effects in the brain via neuroprotective cytokine regulation.
What is the mechanism behind semax's neuroprotective effects?
Following ischemic stroke or brain injury, semax reduces inflammatory cascades that cause secondary neuronal death. It inhibits the overexpression of pro-inflammatory cytokines, reduces oxidative stress in neural tissue, and promotes the survival of damaged neurons. Russian clinical data shows improved outcomes in ischemic stroke patients when semax is administered in the acute phase of injury.
How is semax typically administered?
Semax is predominantly used as an intranasal spray (1-3 drops per nostril) because it crosses the blood-brain barrier efficiently via olfactory neurons when applied nasally. This provides rapid CNS delivery without the need for injection. The intranasal route produces effects within 15-30 minutes. Injectable semax is also available but less common outside clinical settings.
What are the different variants of semax?
There are several semax variants: (1) Standard Semax (base compound); (2) N-Acetyl Semax — acetylated form with potentially enhanced stability and potency; (3) N-Acetyl Semax Amidate — further modified for extended duration of action; and (4) Semax 0.1% vs 1% concentrations for intranasal use. N-Acetyl Semax Amidate is generally considered the most potent form based on anecdotal reports, though head-to-head clinical comparisons are lacking.
Does semax have any mood effects?
Yes. Semax modulates the serotonergic system and influences dopamine receptor expression in the limbic system. Reported effects include improved motivation, reduced anxiety, and enhanced emotional resilience. These effects appear distinct from its cognitive enhancement properties and may be most pronounced in individuals with suboptimal baseline dopaminergic or serotonergic function. Semax is sometimes compared favorably to low-dose seratonergic compounds for anxiety management.
Is semax safe for regular use?
Russian clinical data covering decades of use in hospital settings indicates a favorable acute safety profile. No significant adverse effects on liver enzymes, cardiovascular parameters, or hormonal axes have been reported at standard doses. Long-term effects in healthy individuals are not formally studied. The main practical concern is nasal mucosa irritation with chronic intranasal use. Most research protocols use cyclical administration (5 days on, 2 days off) rather than continuous use.
Clinical Data Matrix
| Parameter | Clinical Value |
|---|---|
| Molecular Weight | Heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) |
| Primary Pathway | Cognitive & Nootropic |
| Research Phase | Pending Reclassification |
Clinical Pros
- Highly selective receptor modulation
- Documented efficacy in Phase II trials
- Minimal systemic cross-reactivity
Research Limitations
- Limited long-term human data
- Strict storage and reconstitution requirements
- Potential for acute homeostatic feedback loops
Community Discussion
Share your questions and experiences with other researchers in the forum.
Discuss in ForumClinical Reference Nodes
Data Verified: 2026-05-31 10:51:59